Higher odds of trial of labor with night float call system

Higher odds of trial of labor with night float call system

(HealthDay)—Physicians working on a night float call system are more likely to have patients with a prior cesarean delivery undergo trial of labor and achieve vaginal birth, according to a study published in the January issue of the American Journal of Obstetrics & Gynecology.

Lynn M. Yee, M.D., M.P.H., from the Northwestern University Feinberg School of Medicine in Chicago, and colleagues examined the correlation between obstetricians' call schedule and obstetric outcomes in a involving women eligible for a trial of labor after cesarean. The authors classified attending obstetrician call schedules as traditional or night float call, which was defined as a schedule in which the provider had clinical responsibilities only for a day or , with no additional responsibilities before or after their period of responsibility.

The researchers found that 37 percent of the 1,502 eligible patients were delivered by physicians in a night float call system. Women cared for by physicians with a night float call schedule were significantly more likely to undergo a trial of labor after cesarean (33.1 versus 16.5 percent) and to achieve a vaginal birth after cesarean (18.7 versus 9.3 percent). After adjustment for confounding variables, these correlations persisted (adjusted odds ratios, 2.64 and 2.17, respectively).

"Using a night float call schedule may be an effective measure to promote a trial of after cesarean and after cesarean," the authors write.

More information: Full Text

Copyright © 2017 HealthDay. All rights reserved.

Citation: Higher odds of trial of labor with night float call system (2017, January 9) retrieved 25 April 2024 from https://medicalxpress.com/news/2017-01-higher-odds-trial-labor-night.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Universal group B streptococci screening not cost-effective

0 shares

Feedback to editors